Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy

Laura S Mertens; Richard P Meijer; J Alfred Witjes

doi:10.1016/j.eururo.2022.09.017

Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy

Laura S Mertens, Richard P Meijer, J Alfred Witjes

Research output: Contribution to journal › Editorial › Academic › peer-review

Abstract

Fluorodeoxyglucose-based positron emission tomography/computed tomography is increasingly being used for staging of muscle-invasive bladder cancer before treatment. However, international clinical guidelines are hesitant to recommend this approach, as conclusive scientific evidence on its usefulness is lacking. The question is whether and how this evidence can be obtained.

Original language	English
Pages (from-to)	95-96
Number of pages	2
Journal	European Urology
Volume	83
Issue number	2
Early online date	3 Oct 2022
DOIs	https://doi.org/10.1016/j.eururo.2022.09.017
Publication status	Published - Feb 2023

Access to Document

10.1016/j.eururo.2022.09.017

Cite this

@article{004b8ebbc73d494fa52a164320b1a837,

title = "Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy",

abstract = "Fluorodeoxyglucose-based positron emission tomography/computed tomography is increasingly being used for staging of muscle-invasive bladder cancer before treatment. However, international clinical guidelines are hesitant to recommend this approach, as conclusive scientific evidence on its usefulness is lacking. The question is whether and how this evidence can be obtained.",

author = "Mertens, {Laura S} and Meijer, {Richard P} and {Alfred Witjes}, J",

year = "2023",

month = feb,

doi = "10.1016/j.eururo.2022.09.017",

language = "English",

volume = "83",

pages = "95--96",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer

T2 - A Continuing Clinical Controversy

AU - Mertens, Laura S

AU - Meijer, Richard P

AU - Alfred Witjes, J

PY - 2023/2

Y1 - 2023/2

N2 - Fluorodeoxyglucose-based positron emission tomography/computed tomography is increasingly being used for staging of muscle-invasive bladder cancer before treatment. However, international clinical guidelines are hesitant to recommend this approach, as conclusive scientific evidence on its usefulness is lacking. The question is whether and how this evidence can be obtained.

AB - Fluorodeoxyglucose-based positron emission tomography/computed tomography is increasingly being used for staging of muscle-invasive bladder cancer before treatment. However, international clinical guidelines are hesitant to recommend this approach, as conclusive scientific evidence on its usefulness is lacking. The question is whether and how this evidence can be obtained.

UR - http://www.scopus.com/inward/record.url?scp=85139203938&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2022.09.017

DO - 10.1016/j.eururo.2022.09.017

M3 - Editorial

C2 - 36202686

SN - 0302-2838

VL - 83

SP - 95

EP - 96

JO - European Urology

JF - European Urology

IS - 2

ER -

Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this